Neuroject ApS: Financial statements 2025
CVR: 43712241
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Neuroject ApS (CVR 43712241) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 326,576 and a net result of DKK -346,903 compared with DKK 67,834 the year before. That is a decrease of 35% compared with the year before. Equity in the 2025 report amounted to DKK -271,762. The company had 1 employee in the financial year.
- Gross Profit
- DKK 326,576
- Profit/Loss
- DKK -346,903
- Equity
- DKK -271,762
- Total Assets
- DKK 120,252
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 327K | -347K | -272K | 1 |
| 2024 | - | 503K | 68K | 75K | 1 |
| 2023 | - | -25K | -33K | 7K | 1 |
Official annual report
How creditworthy is Neuroject ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Neuroject ApS has published its annual report for 2024. Gross profit came to DKK 502,661, and the net result was DKK 67,834.
About Neuroject ApS
Neuroject ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2022. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The management consists of Brian Taammoli. The company is owned by Neural Stem Cell ApS. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 326,576 and a net result of DKK -346,903 compared with DKK 67,834 the year before. Equity in the 2025 report amounted to DKK -271,762.